Firefly Neuroscience (AIFF) said Wednesday it is collaborating with Bright Minds Biosciences (DRUG) to use Firefly's AI-driven Brain Network Analytics technology to analyze data from Bright Minds' phase 1 study of its lead compound, BMB-101.
Financial details weren't disclosed.
The study on Bright Minds' lead compound, BMB-101, utilized electroencephalogram, or EEG headsets from Firefly's partner, Zeto, and showed positive results through qEEG data analysis with recordings taken at multiple time points.
Firefly Neuroscience said that the phase 1 trial is complete, and BMB-101 is now ready for phase 2.
Shares of Firefly were up more than 22%, while Bright Minds retreated over 35% in recent Wednesday trading.
Price: 3.84, Change: +0.71, Percent Change: +22.52
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。